ABVC BioPharma Inc ABVC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $0.72–0.75
- 52-Week Range
- $0.67–5.06
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $8.86 Mil
- Volume/Avg
- 108,189 / 270,823
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 168.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.abvcpharma.com
Valuation
|
Metric
|
ABVC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.99 |
Price/Sales | 168.70 |
Price/Cash Flow | — |
Price/Earnings
ABVC
Financial Strength
|
Metric
|
ABVC
|
|---|---|
Quick Ratio | 0.15 |
Current Ratio | 0.27 |
Interest Coverage | −3.12 |
Quick Ratio
ABVC
Profitability
|
Metric
|
ABVC
|
|---|---|
Return on Assets (Normalized) | −76.07% |
Return on Equity (Normalized) | −187.81% |
Return on Invested Capital (Normalized) | −85.59% |
Return on Assets
ABVC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Trzbccxny | Wxsmp | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wlsvqpkz | Yxnvt | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Czcbyyv | Vnsndz | $117.3 Bil | |||
| Moderna Inc
MRNA
| Mqyqrddv | Pxrp | $46.1 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mqhvqvwdw | Bzvkrx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Nqjlggx | Rcxbp | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Nhcwnrh | Hysxq | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fxjdszqy | Lyjlprc | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tqktxccpq | Rwsm | $14.9 Bil | |||
| Incyte Corp
INCY
| Rqjrymms | Hknkt | $13.5 Bil |